Anti-TNF therapy infliximab (Remicade, Centocor) is now approved for the treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy.
Anti-TNF therapy infliximab (Remicade, Centocor) is now approved for the treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy. The FDA nod marks the 13th indication approved for the drug. In EXPRESS, a phase III clinical trial, eight out of 10 patients receiving induction therapy achieved a 75% improvement in their psoriasis by week 10. Remicade is also approved to treat inflammatory diseases in gastroenterology, dermatology, and rheumatology.
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.